Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989012 | 1.00 | TACR3 (0.75) | TACR3CYP2C9 | |
| SCHEMBL4994642 | 0.97 | TACR3 (0.75) | TACR3CYP2C9 | |
| SCHEMBL4994650 | 0.97 | TACR3 (0.75) | TACR3CYP2C9 | |
| SCHEMBL8267598 | 0.89 | TACR3 (0.78) | TACR3CYP2C9 | |
| SCHEMBL1580871 | 0.86 | CYP2C9 (0.76) | TACR3CYP2C9 | |
| SCHEMBL4961358 | 0.86 | TACR3 (0.82) | TACR3CYP2C9 | |
| SCHEMBL4961350 | 0.86 | TACR3 (0.82) | TACR3CYP2C9 | |
| SCHEMBL1581362 | 0.85 | TACR3 (0.79) | TACR3CYP2C9 | |
| SCHEMBL4668563 | 0.85 | CYP2C9 (0.77) | TACR3CYP2C9 | |
| SCHEMBL14086061 | 0.85 | CYP2C9 (0.74) | TACR3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | KCNQ3, KCNA3, KCNK3 | TACR3 17/4885CYP2C9 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.